project id: TCGA-PRAD; case submitter id: TCGA-J9-A8CL; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.91; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.53; rna integrity number: 7.7; age at index: 66; days to birth: -24145; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1947; age at diagnosis: 24145; ajcc clinical m: M0; ajcc clinical t: T3a; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 405.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 278; initial weight: 80.0; sample id: 778ff135-105c-4389-ab7a-4e5bee6a9de0; sample submitter id: TCGA-J9-A8CL-01A; portion id: 7a344830-bf80-4a4c-b85d-d13e3c1777c7; portion submitter id: TCGA-J9-A8CL-01A-11; slide id: 585776a4-a5e4-4708-81b2-ce0a19b59537; slide submitter id: TCGA-J9-A8CL-01A-01-TS1; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 25.0; percent tumor cells: 75.0; percent tumor nuclei: 85.0; section location: TOP;